These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 12447867)
1. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. King JK; Yeh SH; Lin MW; Liu CJ; Lai MY; Kao JH; Chen DS; Chen PJ Hepatology; 2002 Dec; 36(6):1416-24. PubMed ID: 12447867 [TBL] [Abstract][Full Text] [Related]
2. [Genetic polymorphisms of MxA protein and eIF-2a-reg2 and their responses to interferon treatment in patients with chronic hepatitis B]. Huang YX; Ma LN; Chen XY; Li Z; Huang YL; Shen CL; Ma B Zhonghua Gan Zang Bing Za Zhi; 2007 Mar; 15(3):187-91. PubMed ID: 17407708 [TBL] [Abstract][Full Text] [Related]
3. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370 [TBL] [Abstract][Full Text] [Related]
4. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. Suzuki F; Arase Y; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Takagi K; Satoh J; Kumada H J Viral Hepat; 2004 May; 11(3):271-6. PubMed ID: 15117331 [TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin. Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Hsieh MY; Hou NJ; Lin ZY; Hsieh MY; Wang LY; Yu ML Antiviral Res; 2005 Aug; 67(2):93-7. PubMed ID: 16051377 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673 [TBL] [Abstract][Full Text] [Related]
7. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Tsukada H; Ochi H; Maekawa T; Abe H; Fujimoto Y; Tsuge M; Takahashi H; Kumada H; Kamatani N; Nakamura Y; Chayama K Gastroenterology; 2009 May; 136(5):1796-805.e6. PubMed ID: 19208361 [TBL] [Abstract][Full Text] [Related]
8. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection. Wietzke-Braun P; Maouzi AB; Mänhardt LB; Bickeböller H; Ramadori G; Mihm S Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):991-7. PubMed ID: 16894313 [TBL] [Abstract][Full Text] [Related]
9. Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. Liu CJ; Chen PJ; Lai MY; Chen TC; Wang HY; Huang WL; Kao JH; Chen DS Antivir Ther; 2004 Dec; 9(6):895-903. PubMed ID: 15651748 [TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. van Zonneveld M; Honkoop P; Hansen BE; Niesters HG; Darwish Murad S; de Man RA; Schalm SW; Janssen HL Hepatology; 2004 Mar; 39(3):804-10. PubMed ID: 14999700 [TBL] [Abstract][Full Text] [Related]
11. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648 [TBL] [Abstract][Full Text] [Related]
12. The haplotype of the MxA gene promoter is associated with hepatitis B virus infection in a Chinese population. Cao B; Liu X; Hou F; Li W; Han Z; Zhang Q; Dai Y; Xu C; Qi H Liver Int; 2009 Oct; 29(9):1383-8. PubMed ID: 19744071 [TBL] [Abstract][Full Text] [Related]
13. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137 [TBL] [Abstract][Full Text] [Related]
14. Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H. Erhardt A; Göbel T; Ludwig A; Lau GK; Marcellin P; van Bömmel F; Heinzel-Pleines U; Adams O; Häussinger D J Med Virol; 2009 Oct; 81(10):1716-20. PubMed ID: 19697400 [TBL] [Abstract][Full Text] [Related]
15. Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha. Kansu A; Kuloğlu Z; Demirçeken F; Girgin N Turk J Gastroenterol; 2004 Dec; 15(4):213-8. PubMed ID: 16249973 [TBL] [Abstract][Full Text] [Related]
16. Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients. Tang TJ; de Man RA; Kusters JG; Kwekkeboom J; Hop WC; van der Molen RG; Schalm SW; Janssen HL J Med Virol; 2004 Feb; 72(2):215-22. PubMed ID: 14695662 [TBL] [Abstract][Full Text] [Related]
17. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901 [TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of interferon-gamma, interferon-gamma receptor, and interferon regulatory factor-1 genes in patients with hepatitis B virus infection. Cheong JY; Cho SW; Chung SG; Lee JA; Yeo M; Wang HJ; Lee JE; Hahm KB; Kim JH Biochem Genet; 2006 Jun; 44(5-6):246-55. PubMed ID: 16944293 [TBL] [Abstract][Full Text] [Related]
19. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b. Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284 [TBL] [Abstract][Full Text] [Related]
20. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. Ito N; Eto M; Nakamura E; Takahashi A; Tsukamoto T; Toma H; Nakazawa H; Hirao Y; Uemura H; Kagawa S; Kanayama H; Nose Y; Kinukawa N; Nakamura T; Jinnai N; Seki T; Takamatsu M; Masui Y; Naito S; Ogawa O J Clin Oncol; 2007 Jul; 25(19):2785-91. PubMed ID: 17602083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]